FDA released long-awaited draft guidance Dec. 1 to help pave the way for the development of a fully closed-loop “artificial pancreas” device, which is poised to change the way patients manage type 1 diabetes by automating the process.
The draft outlines what information sponsors should include in investigational device exemption applications needed to begin U.S. clinical trials and...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?